NSIV member, Cellanyx Diagnostics, was awarded the best prostate cancer biomarker poster presentation at the recent 2016 American Urological Association annual meeting. “Cellanyx is currently developing phenotypic tests to address an important unmet clinical need in prostate cancer risk stratification by providing quantitative assessment of tumor aggressiveness and metastatic potential that complements the standard-of-care Gleason pathology scores”, according to the press release.
Read the full press release here and view the poster presentation.
Learn more at www.cellanyx.com.
Leave a Comment